|
[1]FERLAY J, SOERJOMATARAM I, DIKSHIT R, et al.Cancer incidence and mortality worldwide:Sources, methods and major patterns in GLOBOCAN 2012[J].Int J Cancer, 2015, 136 (5) :e359-e386.
|
|
[2]SCHOTTENFELD D, FRAUMENI JF.Cancer epidemiology and prevention[M].3rd ed.New York:Oxford University Press, 2006.
|
|
[3]WU J, YANG S, XU K, et al.Patterns and trends of liver cancer incidence rates in Eastern and Southeastern Asian countries (1983-2007) and predictions to 2030[J].Gastroenterology, 2018, 154 (6) :1719-1728.
|
|
[4]WHO.Graphs:Time trends[EB/OL].http://ci5.iarc.fr/CI5plus/Pages/graph4_sel.aspx.
|
|
[5]NEIL DT, CHEN CJ, MICHAEL CK.Liver cancer (world cancer report) [EB/OL].http://publications.iarc.fr/Non-Series-Publications/World-Cancer-Reports/World-Cancer-Report-2014.
|
|
[6]ACHARYA SK.Epidemiology of hepatocellular carcinoma in India[J].J Clin Exp Hepatol, 2014, 4 (Suppl 3) :s27-s33.
|
|
[7]SRIPA B, KAEWKES S, SITHITHAWORN P, et al.Liver flukeinduces cholangiocarcinoma[J].PLo S Med, 2007, 4 (7) :e201.
|
|
[8]CHIANG CJ, YANG YW, YOU SL, et al.Thirty-year outcomes of the national hepatitis B immunization program in Taiwan[J].JAMA, 2013, 310 (9) :974-976.
|
|
[9]SUN Z, CHEN T, THORGEIRSSON SS, et al.Dramatic reduction of liver cancer incidence in young adults:28 year follow-up of etiological interventions in an endemic area of China[J].Carcinogenesis, 2013, 34 (8) :1800-1805.
|
|
[10]BARTENSCHLAGER R, BAUMERT TF, BUKH J, et al.Critical challenges and emerging opportunities in hepatitis C virus research in an era of potent antiviral therapy:Considerations for scientists and funding agencies[J].Virus Res, 248:53-62.
|
|
[11]LIAW YF, SUNG JJ, CHOW WC, et al.Lamivudine for patients with chronic hepatitis B and advanced liver disease[J].N Engl J Med, 2004, 351 (15) :1521-1531.
|
|
[12]KUMADA T, TOYODA H, TADA T, et al.Effect of nucleos (t) ide analogue therapy on hepatocarcinogenesis in chronic hepatitis B patients:A propensity score analysis[J].J Hepatol, 2013, 58 (3) :427-433.
|
|
[13]IKEDA K, KAWAMURA Y, KOBAYASHI M, et al.Direct-acting antivirals decreased tumor recurrence after initial treatment of hepatitis C virus-related hepatocellular carcinoma[J].Dig Dis Sci, 2017, 62 (10) :2932-2942.
|
|
[14]LEE SH, JIN YJ, SHIN JY, et al.Assessment of hepatocellular carcinoma risk based on peg-interferon plus ribavirin treatment experience in this new era of highly effective oral antiviral drugs[J].Medicine (Baltimore) , 2017, 96 (1) :e5321.
|
|
[15]KANWAL F, KRAMER J, ASCH SM, et al.Risk of hepatocellular cancer in HCV patients treated with direct-acting antiviral agents[J].Gastroenterology, 2017, 153 (4) :996-1005.
|
|
[16]LI DK, REN Y, FIERER DS, et al.The short-term incidence of hepatocellular carcinoma is not increased after hepatitis C treatment with direct-acting antivirals:An ERCHIVES study[J].Hepatology, 2018, 67 (6) :2244-2253.
|
|
[17]WHO.Global health sector strategy on viral hepatitis 2016-2021[EB/OL].http://www.who.int/hepatitis/strategy2016-2021/ghss-hep/en.
|
|
[18]WU J, XU H, HE X, et al.Six-year changes in the prevalence of obesity and obesity-related diseases in Northeastern China from2007 to 2013[J].Sci Rep, 2017, 7:41518.
|
|
[19]MAROT A, HENRION J, KNEBEL JF, et al.Alcoholic liver disease confers a worse prognosis than HCV infection and non-alcoholic fatty liver disease among patients with cirrhosis:An observational study[J].PLo S One, 2017, 12 (10) :e0186715.
|
|
[20]WHO.Global status report on alcohol and health[EB/OL].http://www.who.int/topics/alcohol_drinking/en.
|
|
[21]WANG FS, FAN JG, ZHANG Z, et al.The global burden of liver disease:The major impact of China[J].Hepatology, 2014, 60 (6) :2099-2108.
|
|
[22]Global Burden of Disease Liver Cancer Collaboration, AKINYEMIJU T, ABERA S, et al.The burden of primary liver cancer and underlying etiologies from 1990 to 2015 at the global, regional, and national level:Results from the Global Burden of Disease Study 2015[J].JAMA Oncol, 2017, 3 (12) :1683-1691.
|
DownLoad: